Agalsidase beta (recombinant form) (DrugBank: Agalsidase beta)
1 diseaseID | Disease name (Link within this page) | Number of trials |
---|---|---|
19 | Lysosomal storage disease | 1 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT00233870 (ClinicalTrials.gov) | June 2004 | 5/10/2005 | A Long Term Safety and Efficacy Study of Fabrazyme Replacement Therapy in Japanese Patients With Fabry Disease. | Special Survey in Long-Term Use of Fabrazyme | Fabry Disease | Drug: Agalsidase beta (recombinant form) | Genzyme, a Sanofi Company | NULL | Completed | N/A | N/A | Both | 405 | Japan |